País: Israel
Idioma: inglés
Fuente: Ministry of Health
MEDROXYPROGESTERONE ACETATE
PFIZER PFE PHARMACEUTICALS ISRAEL LTD
G03AC06
SUSPENSION FOR INJECTION
MEDROXYPROGESTERONE ACETATE 150 MG/ML
I.M
Required
PFIZER MANUFACTURING BELGIUM NV/SA
MEDROXYPROGESTERONE
MEDROXYPROGESTERONE
For contraception where medically indicated and oral administration is inapplicable.
2020-12-31
PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS )PREPARATIONS( – 1986 The medicine is dispensed with a doctor’s prescription only DEPO-PROVERA ® 150 MG/ML SUSPENSION FOR INJECTION MEDROXYPROGESTERONE ACETATE 150 MG/ML Inactive and allergenic ingredients: see section 2 under “Important information about some of the ingredients of the medicine” and section 6 “Further information”. READ THE LEAFLET CAREFULLY IN ITS ENTIRETY BEFORE USING THE MEDICINE. This leaflet contains concise information about the medicine. If you have further questions, refer to the doctor or pharmacist. This medicine has been prescribed to treat you. Do not pass it on to others. It may harm them, even if it seems to you that their medical condition is similar to yours. The effectiveness of Depo-Provera ® in the prevention of pregnancy depends on your adherence to receiving an injection of the preparation once every 12 weeks. 1. WHAT IS THE MEDICINE INTENDED FOR? • Depo-Provera ® is a contraceptive agent, when there is a medical indication for this and oral contraceptives (taken by mouth) cannot be used. THERAPEUTIC GROUP: PROGESTOGENS A progesterone derivative – Depo- Provera ® contains the active ingredient medroxyprogesterone acetate, which is chemically similar to the natural hormone progesterone. Progesterone is produced by the ovaries during the second half of the menstrual cycle. Depo-Provera ® prevents the eggs in the ovaries from maturing, thereby preventing their passage from the ovaries into the womb, and therefore, fertilization is not possible and pregnancy is prevented. Depo-Provera ® also acts by changing the lining of the womb, which makes it less likely for pregnancy to occur, and by thickening the mucosa at the entrance of the womb, making it more difficult for sperm to enter. Depo-Provera ® is given as an intramuscular injection ONCE EVERY 12 WEEKS. 2. BEFORE USING THE MEDICINE DO NOT USE THE MEDICINE IF: x You are sensitive (allergic) to the active ingredient or to any of the a Leer el documento completo
DEPO-PROVERA ® 500 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Depo-Provera ® 500 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Depot-medroxyprogesterone acetate injectable suspension is available as 500 mg/3.3 ml vial. Excipients with known effect: Methyl paraben Propyl paraben Sodium chloride For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Suspension for intramuscular injection. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS DEPO-PROVERA ® 500 is indicated for: Palliation of inoperable recurrent or metastatic carcinoma of endometrium, breast, ovary and kidney. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Injectable suspensions should be shaken well before use. The site of injection should be cleansed using standard methods prior to administration of the injection. _RECURRENT AND/OR METASTATIC BREAST CANCER_ INJECTABLE DMPA INITIAL DOSE 500 TO 1000 MG INTRAMUSCULARLY PER DAY FOR 28 DAYS. THE PATIENT SHOULD THEN BE PLACED ON A MAINTENANCE SCHEDULE OF 500 MG TWICE WEEKLY AS LONG AS SHE RESPONDS TO TREATMENT. _RECURRENT AND/OR METASTATIC ENDOMETRIAL OR RENAL CANCER_ INJECTABLE DMPA 400 TO 1000 MG INTRAMUSCULARLY PER WEEK IS RECOMMENDED INITIALLY. IF IMPROVEMENT IS NOTED WITHIN A FEW WEEKS OR MONTHS AND THE DISEASE APPEARS STABILIZED, IT MAY BE POSSIBLE TO MAINTAIN IMPROVEMENT WITH AS LITTLE AS 400 MG PER MONTH. _LONG-TERM USE_ Since loss of bone mineral density (BMD) may occur in pre-menopausal women who use DMPA injection long-term (SEE SECTION 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE AND SECTION 5.1 PHARMACODYNAMIC PROPERTIES, _CLINICAL TRIALS RELATING TO BONE MINERAL DENSITY_), a risk/ benefit assessment, which also takes into consideration the decrease in BMD that occurs during pregnancy and/or lactation, should be considered. _USE IN CHILDREN_ DMPA IM is not indicated before menarche. Data are available in adolescent females (12-18 years) (SEE SECTION 5.1 PHARMACODYNAMIC PROPERTIES, _CLINICAL TRIALS, CHANGES IN _ _BMD IN ADOLESCENT FEMALES (AGED Leer el documento completo